Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Analysis Of The Correlation Between Endorectal MRI Response To Neoadjuvant Chemotherapy And Biochemical Recurrence In Patients With High-risk Localized Prostate Cancer

M. Galsky, W. Xie, M. Nakabayashi, R. Ross, F. Fennessy, C. Tempany, T. Choueiri, K. Khine, P. Kantoff, M. Taplin, W. Oh
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Background:Intermediate end points are desirable to expedite the integration of neoadjuvant systemic therapy into the treatment strategy for high-risk localized prostate cancer. Endorectal magnetic resonance imaging at 1.5 Tesla (1.5T erMRI) response has been utilized as an end point in neoadjuvant trials but has not been correlated with clinical outcomes.Methods:Data were pooled from two trials exploring neoadjuvant chemotherapy in high-risk localized prostate cancer. Trial 1 explored docetaxel for 6 months and Trial 2 explored docetaxel plus bevacizumab for 4.5 months, both before radical prostatectomy. erMRI was done at baseline and end of chemotherapy. 1.5T erMRI response, based upon T2W sequences, was recorded. Multivariable Cox regression was undertaken to evaluate the association between clinical parameters and biochemical recurrence.Results:There were 53 evaluable patients in the combined analysis: 20 (33%) achieved a PSA response, 16 (27%) achieved an erMRI partial response and 24 (40%) achieved an erMRI minor response. Median follow-up was 4.2 years, and 33 of 53 evaluable (62%) patients developed biochemical recurrence. On multivariable analysis, PSA response did not correlate with biochemical recurrence (hazard ratio=0.58, 95% confidence interval (CI) 0.25–1.33) and paradoxically erMRI response was associated with a significantly shorter time to biochemical recurrence (hazard ratio=2.47, 95% CI 1.00–6.13).Conclusions:Response by 1.5T erMRI does not correlate with a decreased likelihood of biochemical recurrence in patients with high-risk localized prostate cancer treated with neoadjuvant docetaxel and may be associated with inferior outcomes. These data do not support the use of 1.5T erMRI response as a primary end point in neoadjuvant chemotherapy trials.
This paper references
neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer
R Dreicer (2008)
10.1001/JAMA.1997.03540420041027
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
A. Partin (1997)
10.1016/j.juro.2011.11.112
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study.
D. Margel (2012)
10.1111/j.1464-410X.2011.10422.x
The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up
E. Antonarakis (2012)
10.1002/SIM.4780080407
Surrogate endpoints in clinical trials: definition and operational criteria.
R. Prentice (1989)
10.1016/S0022-5347(01)62152-9
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.
M. Kattan (1998)
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high - risk localized
RW Ross
10.1200/JCO.2012.30.15_SUPPL.4520
Neoadjuvant androgen pathway suppression prior to prostatectomy.
E. Mostaghel (2012)
10.1016/j.juro.2011.11.084
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era.
A. Kibel (2012)
10.1016/j.juro.2008.04.012
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
K. Chi (2008)
clinical trials consortium trial
SC Partridge (2012)
10.1002/cncr.27416
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer
R. Ross (2012)
10.7326/0003-4819-156-8-201204170-00401
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.
Ying Y. Zhao (2012)
10.1200/JCO.2012.30.15_SUPPL.4521
Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study.
Mary-Ellen Taplin (2012)
National Institutes of Health State-of-the-Science Conference
P. Ganz (2012)
10.1016/j.juro.2011.07.013
Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds.
B. Turkbey (2011)
10.7326/0003-4819-156-8-201204170-00401
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.
P. Ganz (2012)
10.1016/J.UROLOGY.2004.01.040
Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
R. Dreicer (2004)
10.1148/radiol.11091822
Prostate cancer: multiparametric MR imaging for detection, localization, and staging.
C. Hoeks (2011)
10.3322/caac.20138
Cancer statistics, 2012
R. Siegel (2012)
10.1158/1078-0432.CCR-05-0299
Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer
P. Febbo (2005)
10.1200/JCO.2011.39.2779
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
L. Esserman (2012)
10.1016/j.eururo.2008.11.051
A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance.
N. V. van As (2009)
nomogram for disease recurrence following radical prostatectomy for prostate cancer
AW Partin (1998)
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
J. Kirkpatrick (1998)
10.1038/pcan.2012.43
Prostate Cancer and Prostatic Diseases (2012) 15, 313.
Freedland Sj (2012)
agement of men with localized prostate cancer
AS Kibel (2012)
National Institutes of Health StateoftheScience Conference : role of active surveillance in the management of men with localized prostate cancer
PA Ganz (2012)
10.2214/AJR.184.6.01841774
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
S. Partridge (2005)
10.1200/JCO.2008.18.2501
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
A. Stephenson (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar